Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment

Abstract Patients with cirrhosis and impaired coagulation often pose major therapeutic problems during bleeding episodes or invasive procedures. Recombinant activated factor VII (rFVIIa), which has been licensed for the treatment of haemophilia patients with factor VIII or IX inhibitors, has been oc...

Full description

Saved in:

Bibliographic Details
Published in:	Digestive and liver disease Vol. 39; no. 5; pp. 490 - 494
Main Authors:	Tsochatzis, E, Papatheodoridis, G.V, Elefsiniotis, I, Thanelas, S, Theodossiades, G, Moulakakis, A, Archimandritis, A.J
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-05-2007
Subjects:	Adult Aged Blood Coagulation Disorders - drug therapy Cirrhosis Coagulopathy Factor VIIa - therapeutic use Female Gastroenterology and Hepatology Humans Liver Cirrhosis - drug therapy Male Middle Aged Recombinant factor VII Treatment Outcome Cirrhosis Coagulopathy Recombinant factor VII
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!